Couchman Jonathan Form 3 ENZON PHARMACEUTICALS / Brian James Harper ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

COUCHMAN JONATHAN

(Last)

(First)

(Middle)

600 FIFTH AVENUE

2ND FLOOR

(Street)

NEW YORK

10020

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2020

3. Issuer Name and Ticker or Trading Symbol
ENZON PHARMACEUTICALS, INC. [ ENZN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.01 per share⁽¹⁾	4,717,666	I	By Jonathan Couchman⁽²⁾
Common Stock, par value $0.01 per share⁽¹⁾	400,000	I	By Couchman Family Fund⁽³⁾
Common Stock, par value $0.01 per share⁽¹⁾	2,100,524	I	By Xstelos Corp.⁽⁴⁾
Common Stock, par value $0.01 per share⁽¹⁾	633,264	I	By Myrexis, Inc.⁽⁵⁾
Common Stock, par value $0.01 per share⁽¹⁾	1,667,294	I	By Harper Asset Management LLC⁽⁶⁾
Common Stock, par value $0.01 per share⁽¹⁾	0	I	By Michael Pearce⁽⁷⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

1. Name and Address of Reporting Person^*

COUCHMAN JONATHAN

(Last)

(First)

(Middle)

600 FIFTH AVENUE

2ND FLOOR

(Street)

NEW YORK

10020

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Couchman Family Fund

(Last)

(First)

(Middle)

600 FIFTH AVENUE

2ND FLOOR

(Street)

NEW YORK

10020

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Xstelos Corp.

(Last)

(First)

(Middle)

1105 NORTH MARKET STREET

SUITE 1300

(Street)

WILMINGTON

19801

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Myrexis, Inc.

(Last)

(First)

(Middle)

600 FIFTH AVENUE

2ND FLOOR

(Street)

NEW YORK

10020

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Harper Brian James

(Last)

(First)

(Middle)

2248 MARINER DR.

(Street)

LONGMONT

80503

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

HARPER ASSET MANAGEMENT LLC

(Last)

(First)

(Middle)

2248 MARINER DR.

(Street)

LONGMONT

80503

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Pearce Michael Cooper

(Last)

(First)

(Middle)

193 AUDUBON TRAIL

(Street)

CASHIERS

28717

(City)

(State)

(Zip)

Explanation of Responses:

1. This Form 3 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis"), Brian Harper, Harper Asset Management, LLC ("HAM"), and Michael Pearce, (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.

2. Represents shares owned directly by Mr. Couchman. As the sole trustee of the Foundation, Mr. Couchman may be deemed to beneficially own the Shares owned by the Foundation. As the Chief Executive Officer of Xstelos, Mr. Couchman may be deemed to beneficially own the shares of Common Stock owned by Xstelos. As the Chief Executive Officer of Myrexis, Mr. Couchman may be deemed to beneficially own Shares of Common Stock owned by Myrexis.

3. Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.

4. Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.

5. Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.

6. Represents shares owned directly by HAM. Mr. Harper is the President of HAM. By virtue of this relationship, Mr. Harper may be deemed to beneficially own the Shares owned directly by HAM. Mr. Harper expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.

7. Represents shares owned directly by Michael Pearce. Mr. Pearce expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.

	/s/ Jonathan Couchman	08/06/2020
	Couchman Family Fund; By: /s/ Jonathan Couchman, Trustee	08/06/2020
	Xstelos Corp.; By: /s/ Jonathan Couchman, Chief Executive Officer	08/06/2020
	Myrexis, Inc.; By: /s/ Jonathan Couchman, Chief Executive Officer	08/06/2020
	/s/ Jonathan Couchman, attorney-in-fact for Brian Harper	08/06/2020
	Harper Asset Management, LLC; By: /s/ Brian Harper	08/06/2020
	/s/ Jonathan Couchman, attorney-in-fact for Michael Pearce	08/06/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Couchman Jonathan Form 3ENZON PHARMACEUTICALS / Brian James Harper ownership change